Leading the way in Infection Prevention and Wound Care Solutions

Bravida is redefining what’s possible in wound care and infection prevention, with a portfolio of transformative products and technologies that are clinically proven to deliver uncompromising freedom and protection.

Play Video

Our Brands
Men’s Liberty

A discreet external male urinary collection device designed to manage urinary incontinence effectively in combination with world class securement solutions

Silverlon

Wound dressings that have a silver plated technology delivering antimicrobial benefits in the dressing without staining the skin and without increasing bioburden

Anasept

An antimicrobial cleanser, gel and irrigation solution that breaks down and removes micro-organisms in the wound bed without damaging healthy cells and tissue

Silversept

Silversept functions as a long-lasting, antimicrobial barrier by inhibiting the growth of bacteria including the antibiotic resistant strains: MRSA & VRE, as well as, clinically important fungi such as: Candida albicans and Aspergillus niger.

Bravida’s Innovative Solutions Impact Clinical Outcomes:

Wound Care

Chronic wounds impact the quality of life of many people across the globe. For example, in the United States, it affects nearly 2.5% (more than 8 million people).

 

Urology

In the United States, up to 80% of complicated urinary tract infections are attributable to indwelling urinary catheters.

Vascular Access

CLABSIs are associated with a high-cost burden, accounting for approximately $46,000 per case.

Surgical Site Infections

Surgical site infections are the most frequent type of healthcare-associated infections, accounting for 14% − 25% of the total hospital-acquired infections.

Burn

Methicillin-resistant S. aureus now is one of the leading organisms causing invasive infection in burns across the world, with burn units reporting rates of infection greater than 50%.

Mechanical Circulatory Support

The overall mortality for driveline infection was 11.5%.
Hospital-acquired infections during ECMO is 10–12% and their occurrence is likely to be more frequent compared with other critically ill patients.

Evolving evidence is at the heart of who we are. It’s the reason to believe in our products.​

See Our Newest Peer Reviewed Publications below

Some of Our Products

Interested in learning more?

Discover the benefits that Bravida Medical products can offer your patients.

Welcome to Bravida Medical!
Select your country or region:

Product availability varies by location.

Our brands: